Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment

B Shariat-Madar1, D Kolte2, A Verlangieri2, Z Shariat-Madar21College of Literature, Science, and the Arts, University of Michigan, Ann Arbor MI, USA; 2School of Pharmacy, Department of Pharmacology, University of Mississippi, University, MS, USAAbstract: Recently, we serendipitously discovered that...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	B Shariat-Madar, D Kolte, A Verlangieri, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/c9f6b9dea2034e42bdf178ec962e2909
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c9f6b9dea2034e42bdf178ec962e2909
record_format	dspace
spelling	oai:doaj.org-article:c9f6b9dea2034e42bdf178ec962e29092021-12-02T02:33:40ZProlylcarboxypeptidase (PRCP) as a new target for obesity treatment1178-7007https://doaj.org/article/c9f6b9dea2034e42bdf178ec962e29092010-04-01T00:00:00Zhttp://www.dovepress.com/prolylcarboxypeptidase-prcp-as-a-new-target-for-obesity-treatment-a4269https://doaj.org/toc/1178-7007B Shariat-Madar1, D Kolte2, A Verlangieri2, Z Shariat-Madar21College of Literature, Science, and the Arts, University of Michigan, Ann Arbor MI, USA; 2School of Pharmacy, Department of Pharmacology, University of Mississippi, University, MS, USAAbstract: Recently, we serendipitously discovered that mice with the deficiency of the enzyme prolylcarboxypeptidase (PRCP) have elevated &alpha;-melanocyte-stimulating hormone (&alpha;-MSH) levels which lead to decreased food intake and weight loss. This suggests that PRCP is an endogenous inactivator of &alpha;-MSH and an appetite stimulant. Since a modest weight loss can have the most profound influence on reducing cardiovascular risk factors, the inhibitors of PRCP would be emerging as a possible alternative for pharmacotherapy in high-risk patients with obesity and obesity-related disorders. The discovery of a new biological activity of PRCP in the PRCP-deficient mice and studies of &alpha;-MSH function indicate the importance and complexity of the hypothalamic pro-opiomelanocortin (POMC) system in altering food intake. Identifying a role for PRCP in regulating &alpha;-MSH in the brain may be a critical step in enhancing our understanding of how the brain controls food intake and body weight. In light of recent findings, the potential role of PRCP in regulating fuel homeostasis is critically evaluated. Further studies of the role of PRCP in obesity are much needed.Keywords: prolylcarboxypeptidase, melanocyte-stimulating harmone, appetite, weight loss, cardiovascular risk, obesity B Shariat-MadarD KolteA Verlangieriet alDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2010, Iss default, Pp 67-78 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 B Shariat-Madar D Kolte A Verlangieri et al Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment
description	B Shariat-Madar1, D Kolte2, A Verlangieri2, Z Shariat-Madar21College of Literature, Science, and the Arts, University of Michigan, Ann Arbor MI, USA; 2School of Pharmacy, Department of Pharmacology, University of Mississippi, University, MS, USAAbstract: Recently, we serendipitously discovered that mice with the deficiency of the enzyme prolylcarboxypeptidase (PRCP) have elevated &alpha;-melanocyte-stimulating hormone (&alpha;-MSH) levels which lead to decreased food intake and weight loss. This suggests that PRCP is an endogenous inactivator of &alpha;-MSH and an appetite stimulant. Since a modest weight loss can have the most profound influence on reducing cardiovascular risk factors, the inhibitors of PRCP would be emerging as a possible alternative for pharmacotherapy in high-risk patients with obesity and obesity-related disorders. The discovery of a new biological activity of PRCP in the PRCP-deficient mice and studies of &alpha;-MSH function indicate the importance and complexity of the hypothalamic pro-opiomelanocortin (POMC) system in altering food intake. Identifying a role for PRCP in regulating &alpha;-MSH in the brain may be a critical step in enhancing our understanding of how the brain controls food intake and body weight. In light of recent findings, the potential role of PRCP in regulating fuel homeostasis is critically evaluated. Further studies of the role of PRCP in obesity are much needed.Keywords: prolylcarboxypeptidase, melanocyte-stimulating harmone, appetite, weight loss, cardiovascular risk, obesity
format	article
author	B Shariat-Madar D Kolte A Verlangieri et al
author_facet	B Shariat-Madar D Kolte A Verlangieri et al
author_sort	B Shariat-Madar
title	Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment
title_short	Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment
title_full	Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment
title_fullStr	Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment
title_full_unstemmed	Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment
title_sort	prolylcarboxypeptidase (prcp) as a new target for obesity treatment
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/c9f6b9dea2034e42bdf178ec962e2909
work_keys_str_mv	AT bshariatmadar prolylcarboxypeptidaseprcpasanewtargetforobesitytreatment AT dkolte prolylcarboxypeptidaseprcpasanewtargetforobesitytreatment AT averlangieri prolylcarboxypeptidaseprcpasanewtargetforobesitytreatment AT etal prolylcarboxypeptidaseprcpasanewtargetforobesitytreatment
_version_	1718402437321064448

Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment

Ejemplares similares